Literature DB >> 22969996

Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma.

Keiichi Ito1, Hidehiko Yoshii, Takako Asano, Akio Horiguchi, Makoto Sumitomo, Masamichi Hayakawa, Tomohiko Asano.   

Abstract

Erythropoietin (EPO) expression and EPO receptor (EpoR) expression have been demonstrated in various malignant tumors. EPO-EpoR signaling can activate several downstream signal transduction pathways that enhance tumor aggressiveness. The present study was undertaken to evaluate the impact of overexpression of EpoR and elevated serum EPO (sEPO) levels on the clinicopathological features and prognosis of patients with renal cell carcinoma (RCC). EpoR expression was evaluated immunohistochemically in 56 patients. Tumors with a staining intensity greater than that of surrounding proximal tubules were defined as tumors with high EpoR expression. The association between EpoR expression levels and various clinicopathological factors was analyzed. sEPO levels were determined in 138 patients and its correlation to clinicopathological factors was also analyzed, and EpoR expression was determined in surgical specimens removed from 47 of those 138 patients. Patients with high EpoR expression and patients with sEPO elevation had clinicopathological features less favorable than those of other patients. Tumors demonstrating high EpoR expression had a significantly higher number of Ki-67-positive cells compared to those with low EpoR expression. Tumor assemblies in microvessels demonstrated high EpoR expression. Patients whose tumors demonstrated high EpoR expression and those with sEPO elevation had a significantly lower survival rate compared to other patients, and patients with both high EpoR expression and sEPO elevation had an extremely poor prognosis. Microvascular invasion was an independent factor associated with sEPO elevation, suggesting that EPO-EpoR signaling might be important in RCC metastasis. EPO-EpoR signaling may be involved in tumor growth and progression in RCC and the combination of EpoR expression and sEPO levels may effectively predict clinical outcome.

Entities:  

Year:  2012        PMID: 22969996      PMCID: PMC3438591          DOI: 10.3892/etm.2012.513

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  20 in total

1.  Erythropoietin and its lost receptor.

Authors:  Alessio Sturiale; Susanna Campo; Eleonora Crascì; Giuseppe Coppolino; Davide Bolignano; Giovanni Grasso; Michele Buemi
Journal:  Nephrol Dial Transplant       Date:  2007-01-31       Impact factor: 5.992

2.  Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma.

Authors:  Kan Gong; Ning Zhang; Zheng Zhang; Yanqun Na
Journal:  Cancer Biol Ther       Date:  2006-06-15       Impact factor: 4.742

Review 3.  Erythropoietin biology in cancer.

Authors:  Matthew E Hardee; Murat O Arcasoy; Kimberly L Blackwell; John P Kirkpatrick; Mark W Dewhirst
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

4.  Erythropoietin stimulates proliferation of human renal carcinoma cells.

Authors:  C Westenfelder; R L Baranowski
Journal:  Kidney Int       Date:  2000-08       Impact factor: 10.612

5.  Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma.

Authors:  Akio Horiguchi; Tomohiko Asano; Junichi Asakuma; Takako Asano; Makoto Sumitomo; Masamichi Hayakawa
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

6.  Erythropoietin protects against ischaemic acute renal injury.

Authors:  David A Vesey; Catherine Cheung; Betty Pat; Zoltan Endre; Glenda Gobé; David W Johnson
Journal:  Nephrol Dial Transplant       Date:  2004-02       Impact factor: 5.992

7.  Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway.

Authors:  Jun Li; David A Vesey; David W Johnson; Glenda Gobe
Journal:  Cancer Biol Ther       Date:  2007-09-01       Impact factor: 4.742

8.  Calponin h1 expression in renal tumor vessels: correlations with multiple pathological factors of renal cell carcinoma.

Authors:  A H M Manjurul Islam; Takashi Ehara; Haruaki Kato; Masayoshi Hayama; Shinya Kobayashi; Yasuhiko Igawa; Osamu Nishizawa
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

9.  Prognostic significance of erythropoietin expression in human renal cell carcinoma.

Authors:  Agniezka Michael; Ekaterini Politi; Erik Havranek; Catherine Corbishley; Lena Karapanagiotou; Chris Anderson; Kate Relph; Konstantinos N Syrigos; Hardev Pandha
Journal:  BJU Int       Date:  2007-08       Impact factor: 5.588

10.  Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis.

Authors:  Akira Miyajima; Takeo Kosaka; Tomohiko Asano; Takako Asano; Kaori Seta; Toshiaki Kawai; Masamichi Hayakawa
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more
  4 in total

1.  Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.

Authors:  Tania Romina Stoyanoff; Juan Pablo Rodríguez; Juan Santiago Todaro; Joaquín Diego Espada; Juan Pablo Melana Colavita; Nora Cristina Brandan; Adriana Mónica Torres; María Victoria Aguirre
Journal:  Tumour Biol       Date:  2016-07-28

2.  Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines.

Authors:  Yutaka Fujisue; Takatoshi Nakagawa; Kiyoshi Takahara; Teruo Inamoto; Satoshi Kiyama; Haruhito Azuma; Michio Asahi
Journal:  Oncol Lett       Date:  2013-04-03       Impact factor: 2.967

3.  Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.

Authors:  Makito Miyake; Steve Goodison; Adrienne Lawton; Ge Zhang; Evan Gomes-Giacoia; Charles J Rosser
Journal:  J Hematol Oncol       Date:  2013-09-03       Impact factor: 17.388

4.  Erythropoietin production in renal cell carcinoma and renal cysts in autosomal dominant polycystic kidney disease in a chronic dialysis patient with polycythemia: A case report.

Authors:  Keiichi Ito; Takako Asano; Susumu Tominaga; Hidehiko Yoshii; Harutake Sawazaki; Tomohiko Asano
Journal:  Oncol Lett       Date:  2014-08-21       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.